Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

This publication has 8 references indexed in Scilit:

• Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
  Oncogene, 2007
• Microfluidic Digital PCR Enables Multigene Analysis of Individual Environmental Bacteria
  Science, 2006
• Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)
  Leukemia, 2006
• Evaluating markers for the early detection of cancer: overview of study designs and methods
  Clinical Trials, 2006
• High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
  Blood, 2005
• ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia
  Journal of Clinical Oncology, 2005
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
  Blood, 2004
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
  Blood, 2003